Home > Treatment Options > Tumor Suppressors > Clinical Trials >

Axitinib (Inlyta™)

Last Updated: 02/16/18

Status: Currently a NF2 Clinical Trial


Chemical Structure, Axitinib
Synonyms: Axitinib, Inlyta, 319460-85-0, AG-013736, AG 013736,
UNII-C9LVQ0YUXG, AG013736, S1005_Selleck,
AG-013736, AG-13736
Trade Name: Inlyta™
Pharmaceutical Company Pfizer
Legal Status: ℞ - Prescription/Under Clinical Trial
Treatment By: Pill - Oral
Tumor Target: Vestibular Schwannoma
Protein Target: TKI and VEGF Inhibitor
NF2 Trials: Recruiting Trial: NCT02129647
Formula: C22H18N4OS
ChemSpider: 4953153
PubChem: CID 6450551

Reccomendations:

  • Drinking extra water or diluted fluids as well as avoiding fatty, fried, spicy, or highly sweet foods can help with many of the potential side effects.
  • Take Axitinib at night instead of the morning to prevent fatigue.

Other Known Uses

  • Breast Cancer
  • Renal Cell Carcinoma (RCC)
  • In Research for: Mesothelioma

Side Effects

  • High Blood Pressure / Nosebleeds
  • Diarrhea
  • Fatigue / Tiredness
  • Decrease in Appetite
  • Nausea / Vomiting
  • Hoarseness / Dry Thrroat
  • Skin Conditions - Dry Skin and Blisters
  • Constipation

Sources

  1. Petrilli, Alejandra M., et al. "Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells." Oncotarget 8.19 (2017): 31666.
    Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458238/ | DOI: 10.18632/oncotarget.15912

  2. Reveal, AI-Enabled Phenotypic Screens. "Clinically Relevant Drugs." (2012)
    Source: https://recursionpharma.com/wp-content/uploads/2017/09/AI-Enabled_Pheno-9_25_2017v24.pdf

  3. Meric-Bernstam, Funda, et al. "A decision support framework for genomically informed investigational cancer therapy." Journal of the National Cancer Institute 107.7 (2015): djv098.
    Source: https://academic.oup.com/jnci/article/107/7/djv098/913288 | DOI: 10.1093/jnci/djv098

  4. Karajannis, Matthias A., and Rosalie E. Ferner. "Neurofibromatosis-related tumors: emerging biology and therapies." Current opinion in pediatrics 27.1 (2015): 26.
    Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374132/ | DOI: 10.1097/MOP.0000000000000169

  5. Shaw, Adam. "Diagnosis and Management of Hereditary Meningioma and Vestibular Schwannoma." Rare Hereditary Cancers. Springer, Cham, 2016. 17-27.
    Source: https://link.springer.com/chapter/10.1007/978-3-319-29998-3_2 | DOI: 10.1007/978-3-319-29998-3_2
    Widemann, Brigitte C., and Scott R. Plotkin. "Consensus for NF clinical trials Recommendations of the REiNS collaboration (Supplement II)." (2016): S1-S3.
    Source: https://link.springer.com/chapter/10.1007/978-3-319-29998-3_2 | DOI:
What is NF2? | About Us | Treatment Options | Sitemap

Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2008 - 2019